ACE2 and COVID-19: While it could be postulated that treatment with ACEI/ARBs increasing ACE2 levels might increase risk of SARS-COV-2 infection severity, recent studies showed that continuation of these drugs in COVID-19 patients was not associated with such risk (Mancia et al., 2020; Mehra et al., 2020; Reynolds et al., 2020).